Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 first-in-human single- and multiple-ascending-dose study of EYP001a in healthy men
NL-OMON42859Phase 1Active, not recruiting
- Sponsor
- ENYO Pharma
- Start
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vonafexor in Chronic Hepatitis B (CHB) (10 arms), sponsored by ENYO Pharma. Started Aug 2016; status: active, not recruiting.
02
Drugs
vonafexor
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON42859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42859.